Inhibition of USP1 ameliorates hypertensive nephropathy through regulating oxidative stress and ferroptosis: a precise treatment via SJB3-019A nanodelivery

Hypertensive nephropathy is second only to diabetes for the causation of chronic kidney disease worldwide. As the mortality and morbidity of hypertensive nephropathy keep increasing, it is important to elucidate its pathogenesis and develop new treatment strategies. In this study, an angiotensin II (Ang II)-induced renal cell system was established, and the expression of ubiquitin specific peptidase 1 (USP1) in human kidney (HK-2) cells was found to be regulated by Ang II treatment through quantitative RT-PCR and Western blot assay. The detection of Glutathione Peroxidase (GSH-Px), malondialdehyde (MDA) and lipid Reactive Oxygen Species (ROS) levels revealed that interference with USP1 reversed Ang II-induced oxidative stress and Ferroptosis, which was enhanced by overexpression of USP1. Subsequently, USP1 Inhibitor SJB3-019A loaded in MIL-100 and PEGTK was modified to fabricate SJB3-019A@MIL-PEGTK nanoparticles, which was confirmed to exhibit excellent alleviation of hypertension-induced oxidative stress and Ferroptosis in renal cells both in vitro and in vivo. Our study identified an important pathogenesis of hypertensive nephropathy and SJB3-019A@MIL-PEGTK nanoparticle was used to develop an effective clinical treatment for hypertensive nephropathy.

MIL-100(Fe); USP1; ferroptosis; hypertensive nephropathy; nanoparticles; oxidative stress.